Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A
cycle equals 21 days and therapy will continue until radiographic progression, intolerable
toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles
may be administered. On Day 1, when both pembrolizumab and lenvatinib are administered,
patients should take the lenvatinib per their normal routine.